Annexure 2

Disclosure regarding Employees Stock Option Scheme (ESOS) pursuant to Rule 12(9) of Companies (Share Capital and Debentures) Rules, 2014 and Regulation 14 of SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021.

1) Details related to the Scheme:

As on 31st March 2026, the Company has in place the Newgen Employees Stock Option Scheme – 2014 ("**Newgen ESOP Scheme 2014**"). This scheme complies with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("Regulations") and Companies Act 2013. All the relevant details as prescribed under above Rule and Regulations are provided below and the same is also available on the website of the Company at https://newgensoft.com/company/investor-relations/#corporate-governance.

A. Relevant disclosures in terms of the 'Guidance note on accounting for employee share-based payments' issued by ICAI or any other relevant accounting standards as prescribed from time to time.

Please refer Note 35– Share Based Payment, of Notes to the Standalone Financial Statements forming part of the Annual Report.

B. Diluted EPS on the issue of shares pursuant to the scheme covered under the regulations in accordance with 'Indian Accounting Standard (Ind AS) - 33 - Earnings Per Share' or any other relevant accounting standards as prescribed from time to time.

Fully diluted EPS pursuant to issue of Equity Shares on exercise of ESOPs calculated in accordance with Ind AS - 33 'Earning Per Share' (Consolidated)	Basic: 21.23 Diluted: 20.88

C. Other Details relating to Newgen ESOP 2014.

S. No.	Particulars	Financial Year 2026
i.	a) Date of shareholders' approval	As on 31st March 2026, the Company has in place the Newgen Employee Stock Option Scheme – 2014 ("Newgen ESOP Scheme 2014"), as approved by the shareholders on 13th November 2014, which was further amended and modified on 28th July 2017 by the shareholders of the Company, to be compliant with the amended SEBI (Share Based Employee Benefits) Regulations, 2014 during IPO procedure. Post initial public offer of the Company, the shareholders ratified the Newgen ESOP 2014 Scheme on 9th August 2018, as required under SEBI (Share Based Employee Benefits) Regulations, 2014. This Scheme was further amended by the Board of Directors on 25th October 2021 and by the Shareholders of the Company on 23rd June 2022, to be compliant with the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021.
	b) Total number of options approved	39,07,023* options are approved under the Scheme subject to necessary adjustment in case of any corporate action. **Pursuant to the adjustment on account of the bonus issue in the ratio of 1:1, as approved by the shareholders of the Company on 2nd January 2024, the option pool under the Scheme was increased by 1,23,223 ESOPs convertible into the equal number of equity shares.*
	c) Vesting requirements	Set forth below is the vesting schedule, subject to there being a gap of at least one year between the date of grant of options and the vesting of such options.

Number of options vested	Vesting schedule
10% of the options granted	One year from the date of grant
20% of the options granted	Two years from the date of grant
30% of the options granted	Three years from the date of grant
40% of the options granted	Four years from the date of grant

S. No.	Particulars	Financial Year 2026
	d) Exercise price or pricing formula	₹ 63
	e) Maximum term of options granted	Once the options have vested, such options have to be exercised within a period of five years from the date on which the last of the options vest. The Vesting period shall be as stated in above point (c).
	f) Source of shares (primary, secondary or combination)	The Company uses Trust Route for implementing this Scheme. The source of Share to the Trust as on 31st March 2026 is Primary. For more information, please refer details related to Newgen ESOP Trust as provided in this disclosure.
	g) Variation in terms of options	NIL
ii.	Method used to account for NEWGEN ESOP 2014(Intrinsic or fair value)/	Fair Value Method using Black-Scholes Model
iii.	Where the Company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognised if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the Company shall also be disclosed.	No ESOPs were granted during the financial year.

iv. Option movement during the year

S. No.	Particulars	Financial Year 2026
a)	Number of options outstanding at the beginning of the year	3,52,780
b)	Number of options granted during the year	NIL
c)	Number of options forfeited / lapsed during the year	NIL
d)	Number of options vested during the year	15,300
e)	Number of options exercised during the year	2,05,210
f)	Number of shares arising as a result of exercise of options	2,05,210
g)	Money realized by exercise of options (INR), if the Scheme is implemented directly by the company	64,84,590
h)	*Loan repaid by the Trust during the year from exercise price received	NIL
i)	Number of options outstanding at the end of the year	1,47,570
j)	Number of options exercisable at the end of the year	94,870

**no loan is outstanding under this Scheme.*

v.	Weighted-average exercise prices and weighted-average fair values of options are disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock.	No ESOPs were granted during the financial year

vi.	**Employee wise details of the options granted during the year:**	
	a. Option granted to Senior Managerial Personnel & KMPs during the year	NIL
	b. Any other employee who receives a grant in any one year of option amounting to 5% or more of option granted during that year under the Scheme.	NIL
	c. Identified employees who were granted option during any one year equal to or exceeding 1% of the issued capital of the Company (excluding outstanding warrants and conversions) at the time of grant.	NIL

vii. A description of the method and significant assumptions used during the year to estimate the fair value of options including the following information:

Particulars	Newgen ESOP Trust (For Newgen ESOP 2014)
Date of grant Fair value of options at grant date Share price at grant date Exercise price Expected volatility (weighted-average) Expected life (weighted-average) Expected dividends Risk-free interest rate (based on government bonds)	No ESOPs were granted during the financial year.
How expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility	Historical volatility for the entire period has been taken since the shares are listed on the stock exchange.
The method used and the assumptions made to incorporate the effects of expected early exercise	The fair value of the employee share options has been measured using the Black-Scholes formula which presumes the option will be exercised at the end of the term.
whether and how any other features of the option grant were incorporated into the measurement of fair value, such as a market condition	Yes. That has already taken effect through volatility and risk-free rate.

2. Details Related to Trust:

Newgen ESOP Scheme 2014 will continue to be implemented through the Trust Route and accordingly, Newgen ESOP Trust was constituted for Newgen ESOP Scheme 2014. In Trust Route, the Trust will utilize the shares already held by it and will acquire the shares of the company either through fresh allotment from the company or by way of secondary acquisition, if any.

(i) Details:

S. No.	Particulars	Newgen ESOP Trust (For Newgen ESOP 2014)
1.	Name of the Trust	Newgen ESOP Trust
2.	Details of the Trustee (s)	Mr. Amarendra Kishore Sharan and Mr. Arun Aggarwal
3.	Amount of loan disbursed by the company/ any company in the group during the year	NIL
4.	Amount of loan outstanding (repayable to company/ any company in the group) as at the end of the year	NIL
5.	Amount of loan, if any, taken from any other source for which the company or any company in the group has provided any security or guarantee	NIL
6.	Any other contribution made to the Trust during the year	NIL

(ii) Brief details of transactions in shares by the Trust:

S. No.	Particulars	Newgen ESOP Trust (For Newgen ESOP 2014)
1.	Number of shares held at the beginning of the year	1,91,386
2.	Number of shares acquired during the year through (i) primary issuance (ii) secondary acquisition, also as a percentage of paid-up equity capital as at the end of the previous financial year, along with information on weighted average cost of acquisition per share	1,00,000
3.	Number of shares transferred to the employees / sold along with the purpose thereof	2,05,210
4.	Number of shares held at the end of the year.	86,176

(iii) In case of secondary acquisition of shares by the Trust:

Number of shares	As a percentage of paid-up equity capital as at the end of the year immediately preceding the year in which shareholders' approval was obtained
	Newgen ESOP Trust
Held at the beginning of the year	NIL
Acquired during the year	NIL
Sold during the year	NIL
Transferred to the employees during the year	NIL
Held at the end of the year	NIL

For and on behalf of Board of Directors

Diwakar Nigam
Chairman & Managing Director
DIN: 00263222

Date: 29.05.2026
Place: New Delhi

Annexure -2A

Disclosure regarding Employees Stock Option Scheme (ESOS) pursuant to Rule 12(9) of Companies (Share Capital and Debentures) Rules, 2014 and Regulation 14 of SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021.

1. Details related to the Scheme:

As on 31st March 2026, the Company has in place the Newgen Employees Stock Option Scheme – 2022 ("**Newgen ESOP Scheme 2022**"). This scheme complies with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("Regulations") and Companies Act 2013. All the relevant details as prescribed under above Rule and Regulations are provided below and the same is also available on the website of the Company at https://newgensoft.com/company/investor-relations/#corporate-governance.

A. Relevant disclosures in terms of the 'Guidance note on accounting for employee share-based payments' issued by ICAI or any other relevant accounting standards as prescribed from time to time.

Please refer Note 35– Share Based Payment, of Notes to the Standalone Financial Statements forming part of the Annual Report.

B. Diluted EPS on issue of shares pursuant to the scheme covered under the regulations in accordance with 'Indian Accounting Standard (Ind AS) - 33 - Earnings Per Share' or any other relevant accounting standards as prescribed from time to time.

Fully diluted EPS pursuant to issue of Equity Shares on exercise of ESOPs calculated in accordance with Ind AS - 33 'Earning Per Share' (Consolidated)	Basic: 21.23 Diluted: 20.88

C. Other Details relating to Newgen ESOP 2022.

S. No.	Particulars	Financial Year 2026
i.	a) Date of shareholders' approval	As on 31st March 2026, the Company has in place the Newgen Employee Stock Option Scheme – 2022 ("Newgen ESOP Scheme -2022"), as approved by the shareholders on 23rd June 2022. The Scheme was subsequently amended on 25th July 2024 by the shareholders of the Company, inter alia, to increase the pool of stock options and to incorporate other modifications in the Newgen ESOP Scheme – 2022.
	b) Total number of options approved	The maximum number of 42,00,000 shares* can be issued under this scheme. **Consequent to the adjustment related to the Bonus issue in the ratio of 1:1, as approved by the members of the Company on 2nd January 2024 the pool of the Scheme was increased from 14,00,000 to 28,00,000 ESOPs convertible into the equal number of equity shares.* **Added further 14,00,000 shares in the Scheme with the approval of shareholders on 25th July 2024.*
	c) Vesting requirements	Set forth below is the vesting schedule, subject to there being a gap of at least one year between the date of grant of options and the vesting of such options. **Number of options vested** — **Vesting schedule** 10% of the options granted — One year from the date of the grant 20% of the options granted — Two years from the date of the grant 30% of the options granted — Three years from the date of the grant 40% of the options granted — Four years from the date of the grant
	d) Exercise price or pricing formula	The Exercise Price of the Shares in the Scheme will be based upon the Market Price, along with a maximum discount of 10%, as approved by the Nomination & Remuneration Committee.

S. No.	Particulars	Financial Year 2026
	e) Maximum term of options granted	Once the options have vested, such options have to be exercised within a period of five years from the date on which the last of the options vest. The vesting period shall be as stated in above point (c).
	f) Source of shares (primary, secondary or combination)	Company uses Trust Route for implementing this Scheme. The source of Share to the Trust as on 31st March 2026 is Primary. For more information, please refer details related to Newgen ESOP Trust as provided in this disclosure.
	g) Variation in terms of options	NIL
ii.	Method used to account for NEWGEN ESOP 2014(Intrinsic or fair value)/	Fair Value Method using Black-Scholes Model
iii.	Where the Company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognised if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the Company shall also be disclosed.	During the financial year 2025-26, Company followed fair value accounting of stock options.

iv. Option movement during the year

S. No.	Particulars	Financial Year 2026
a)	Number of options outstanding at the beginning of the year	27,43,594
b)	Number of options granted during the year	93,300
c)	Number of options forfeited / lapsed during the year	3,28,040
d)	Number of options vested during the year	6,22,040
e)	Number of options exercised during the year	3,06,144
f)	Number of shares arising as a result of exercise of options	3,06,144
g)	Money realized by exercise of options (INR), if the Scheme is implemented directly by the company	6,54,62,953.60
h)	Loan repaid by the Trust during the year from exercise price received	3,76,05,438 (including interest of Loan)
i)	Number of options outstanding at the end of the year	22,02,710
j)	Number of options exercisable at the end of the year	5,94,080

v.	Weighted-average exercise prices and weighted-average fair values of options disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock.	• Weighted-average exercise prices: ₹ 546.31/- • Weighted-average fair values of options granted during the year: NA

vi.	**Employee wise details of the options granted during the year:**	
	a. Option granted to Senior Managerial Personnel & KMPs during the year	NIL
	b. Any other employee who receives a grant in any one year of option amounting to 5% or more of option granted during that year	See table below
	c. Identified employees who were granted option during any one year equal to or exceeding 1% of the issued capital of the Company (excluding outstanding warrants and conversions) at the time of grant.	Not Applicable

Employee Name	Employee Designation	Grant Name	Option Granted	Grant Date
Atul Srivastava	AVP	ESOP 2022/IX	7400	1.05.2025
Dhiraj Kumar Tyagi	AVP	ESOP 2022/IX	7200	1.05.2025
Shantanu Tewari	AVP	ESOP 2022/IX	7100	1.05.2025
Harjan Singh Cheema	AVP	ESOP 2022/IX	9600	1.05.2025
Kingshuk Narayan Nath	AVP	ESOP 2022/IX	12000	1.05.2025
Manish Jaiswal	VP	ESOP 2022/IX	25000	1.05.2025
Rana Ganguli	VP	ESOP 2022/IX	25000	1.05.2025

vii. A description of the method and significant assumptions used during the year to estimate the fair value of options including the following information:

Particulars	**ESOP Grant in Financial Year 2025-26 Grant IX**
Date of grant	**01-05-2025**
Fair value of options at grant date	506.42
Share price at grant date	986.55
Exercise price	888
Expected volatility (weighted-average)	48.41%
Expected life (weighted-average)	5 Years
Expected dividends	0.85%
Risk-free interest rate (based on government bonds)	5.96% - 6.13%
How expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility	Historical volatility for the entire period has been taken since the shares are listed in the stock exchange.
The method used and the assumptions made to incorporate the effects of expected early exercise	The fair value of the employee share options has been measured using the Black-Scholes formula which presumes the option will be exercised at the end of the term.
whether and how any other features of the option grant were incorporated into the measurement of fair value, such as a market condition	Yes. That has already taken effect through volatility and risk-free rate.

2. Details Related to Trust:

Newgen ESOP Scheme 2022 will continue to be implemented through the Trust Route and accordingly, Newgen ESOP Trust was constituted for Newgen ESOP Scheme 2022. In Trust Route, the Trust will utilize the shares already held by it and will acquire the shares of the company either through fresh allotment from the company or by way of secondary acquisition, if any.

(i) Details:

S. No.	Particulars	Newgen ESOP Trust (For Newgen ESOP 2022)
1.	Name of the Trust	Newgen ESOP Trust
2.	Details of the Trustee (s)	Mr. Amarendra Kishore Sharan and Mr. Arun Aggrawal
3.	Amount of loan disbursed by the company/ any company in the group during the year	₹ 21,73,09,240
4.	Amount of loan outstanding (repayable to the Company/ any company in the group) as at the end of the year	Loan:- ₹ 29,41,10,300/- Interest:- ₹ 1,08,26,104/-
5.	Amount of loan, if any, taken from any other source for which the company or any company in the group has provided any security or guarantee	NIL
6.	Any other contribution made to the Trust during the year	NIL

(ii) Brief details of transactions in shares by the Trust under this specific Scheme:

S. No.	Particulars	Newgen ESOP Trust (For Newgen ESOP 2022)
1.	Number of shares held at the beginning of the year (under this Scheme 2022)	3,85,829
2.	Number of shares acquired during the year through (i) primary issuance (ii) secondary acquisition, also as a percentage of paid-up equity capital as at the end of the previous financial year, along with information on weighted average cost of acquisition per share	Primary issuance: 5,92,600 shares. Secondary acquisition: NIL
3.	Number of shares transferred to the employees / sold along with the purpose thereof	3,06,144
4.	Number of shares held at the end of the year.	6,72,285

(iii) In case of secondary acquisition of shares by the Trust:

Number of shares	As a percentage of paid-up equity capital as at the end of the year immediately preceding the year in which shareholders' approval was obtained
	Newgen ESOP Trust
Held at the beginning of the year	NIL
Acquired during the year	NIL
Sold during the year	NIL
Transferred to the employees during the year	NIL
Held at the end of the year	NIL

For and on behalf of Board of Directors

Diwakar Nigam
Chairman & Managing Director
DIN: 00263222

Date: 29.05.2026
Place: New Delhi

Annexure -2B

Disclosure regarding Restricted Stocks Units (RSU) pursuant to Rule 12(9) of Companies (Share Capital and Debentures) Rules, 2014 and Regulation 14 of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

1. Details related to the Scheme:

As on 31st March 2026, the Company has also in place the Newgen Software Technologies Restricted Stock Units Scheme – 2021 ("**Newgen RSU 2021- Scheme**"). This scheme complies with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("Regulations") and Companies Act 2013. All the relevant details as prescribed under the above Rule and Regulations are provided below and the same is also available on the website of the Company at https://newgensoft.com/company/investor-relations/#corporate-governance.

A. Relevant disclosures in terms of the 'Guidance note on accounting for employee share-based payments' issued by ICAI or any other relevant accounting standards as prescribed from time to time.

Please refer Note number 35 – Share-Based Payment, of Notes to the Standalone Financial Statements forming part of the Annual Report.

B. Diluted EPS on issue of shares pursuant to the scheme covered under the regulations in accordance with 'Indian Accounting Standard (Ind AS) - 33 - Earnings Per Share' or any other relevant accounting standards as prescribed from time to time:

Fully diluted EPS pursuant to issue of Equity Shares on exercise of RSUs calculated in accordance with Ind AS - 33 'Earning Per Share' (Consolidated)	Basic: 21.23 Diluted: 20.88

C. Other Details relating to Newgen RSU - 2021

S. No.	Particulars	Financial Year 2026
i.	a) Date of shareholders' approval	The Newgen Software Technologies Restricted Stock Units Scheme – 2021 ("Newgen RSU 2021 - Scheme"), was approved by the shareholders on 26th December 2020, which was further amended on 25th October 2021 by the Board of Directors of the Company, to be compliant with the amended SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021. This Scheme is further amended on 23rd June 2022 by the Shareholders of the Company, to be compliant with the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021.
	b) Total number of RSUs approved	The maximum number of 28,00,000 shares can be issued under this Scheme. **Consequent to the adjustment related to the Bonus issue in the ratio of 1:1, as approved by the members of the Company on 2nd January 2024 the pool of the Scheme was increased from 14,00,000 to 28,00,000 RSUs convertible into the equal number of equity shares.*
	c) Total number of RSUs granted during the year.	NIL
	d) Vesting requirements	Set forth below is the vesting schedule, subject to the performance matric and eligibility: **Time Period** — **% of RSUs to be vested** At the end of 3rd year from the grant date — 50% of the RSUs Granted At the end of 5th year from the grant date — 50% of the RSUs Granted **Vesting schedule is subject to the performance matric as defined in the Scheme.*
	e) Exercise price or pricing formula	₹ 10/- each RSU

S. No.	Particulars	Financial Year 2026
	f) Maximum term of RSUs granted	Once the RSUs have vested, such RSUs have to be exercised within a period of five years from the date on which the last of the RSUs vest. The vesting period shall be as stated in above point (d).
	g) Source of shares (primary, secondary or combination)	Company uses Trust Route for implementing this Scheme. For more information, please refer to details related to Newgen RSU Trust as provided in this disclosure.
	h) Variation in terms of RSUs	NIL
ii.	Method used to account for NEWGEN RSU 2021(Intrinsic or Fair value)	Fair value method
iii.	Where the Company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognised if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the Company shall also be disclosed	No RSUs were granted during the financial year.

iv. RSUs movement during the year

S. No.	Particulars	Financial Year 2026
a)	Number of RSUs outstanding at the beginning of the year	25,29,025
b)	Number of RSUs granted during the year	NIL
c)	Number of RSUs forfeited / lapsed during the year	4,17,077*
d)	Number of RSUs vested during the year	NIL
e)	Number of RSUs exercised during the year	4,35,208
f)	Number of shares arising as a result of exercise of RSUs	4,35,208
g)	Money realized by exercise of RSUs (INR), if scheme is implemented directly by the Company	21,76,040
h)	Loan repaid by the Trust during the year from exercise price received	49,84,318 (including interest of Loan)
i)	Number of RSUs outstanding at the end of the year	16,76,740
j)	Number of options exercisable at the end of the year	7,04,295

**This includes the RSU forfeited/ lapsed due to non achievement of target till 31st March 2026.*

v.	Weighted-average exercise prices and weighted-average fair values of RSUs disclosed separately for RSUs whose exercise price either equals or exceeds or is less than the market price of the stock.	No RSUs were granted during the financial year.

vi.	**Employee wise details of the RSUs granted during the year:**	
	a. RSUs granted to Senior Managerial Personnel & KMPs during the year	NIL
	b. Any other employee who receives a grant in any one year of RSUs amounting to 5% or more of RSUs granted during that year.	NIL
	c. Identified employees who were granted RSUs during any one year equal to or exceeding 1% of the issued capital of the Company (excluding outstanding warrants and conversions) at the time of grant.	NIL

vii. A description of the method and significant assumptions used during the year to estimate the fair value of RSUs including the following information:

Particulars	Newgen RSU Trust
Fair value of options at grant date	No RSUs were granted during the financial year.
Share price at grant date	
Exercise price	
Expected volatility (weighted-average)	
Expected life (weighted-average)	
Expected dividends	
Risk-free interest rate (based on government bonds)	
The method used and the assumptions made to incorporate the effects of expected early exercise	The fair value of the employee share RSUs has been measured using the Black-Scholes formula which presumes the RSUs will be exercised at the end of the term.
How expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility.	The fair value of the employee share options has been measured using the Black-Scholes formula which presumes the RSUs will be exercised at the end of the term.
Whether and how any other features of the RSUs grant were incorporated into the measurement of fair value, such as a market condition.	Yes. That has already taken effect through volatility and risk-free rate.

2. Details Related to Trust:

Newgen RSU 2021- Scheme will continue to be implemented through the Trust Route and accordingly, Newgen RSU Trust was constituted to implement the Scheme. In the Trust Route, the Trust will acquire the shares of the Company either through fresh allotment from the Company or by way of secondary acquisition, if any.

(i) Details:

S. No.	Particulars	Newgen RSU Trust
1.	Details of the Trustee (s)	Mr. Rajesh Pathak Mr. Arun Aggarwal
2.	Amount of loan disbursed by the company/ any company in the group during the year	NIL
3.	Amount of loan outstanding (repayable to Company/ any company in the group) as at the end of the year	Principle: NIL Interest : NIL
4.	Amount of loan, if any, taken from any other source for which the company or any company in the group has provided any security or guarantee	NIL
5.	Any other contribution made to the Trust during the year	NIL

(ii) Brief details of transactions in shares by the Newgen RSU Trust:

S. No.	Particulars	Newgen RSU Trust
1.	Number of shares held at the beginning of the year	8,35,025
2.	Number of shares acquired during the year through (i) primary issuance (ii) secondary acquisition, also as a percentage of paid-up equity capital as at the end of the previous financial year, along with information on weighted average cost of acquisition per share	NIL
3.	Number of shares transferred to the employees / sold along with the purpose thereof	4,35,208
4.	Number of shares held at the end of the year.	3,99,817

(iii) In case of secondary acquisition of shares by the Trust:

Number of shares	As a percentage of paid-up equity capital as at the end of the year immediately preceding the year in which shareholders' approval was obtained
	Newgen RSU Trust
Held at the beginning of the year	NIL
Acquired during the year	NIL
Sold during the year	NIL
Transferred to the employees during the year	NIL
Held at the end of the year	NIL

For and on behalf of Board of Directors

Diwakar Nigam
Chairman & Managing Director
DIN: 00263222

Date: 29.05.2026
Place: New Delhi